Enhanced elimination of warfarin during treatment with cholestyramine
- PMID: 656283
- PMCID: PMC1429341
- DOI: 10.1111/j.1365-2125.1978.tb01651.x
Enhanced elimination of warfarin during treatment with cholestyramine
Abstract
1 The elimination and anticoagulant activity of a single intravenous dose of warfarin (1.0-1.2 mg/kg) without and with concomitant cholestyramine treatment (about 4 g three times daily) was studied in five healthy male subjects. 2 Cholestyramine treatment decreased the biological half-life of plasma warfarin (from a mean value of 2 days -1.3 days) and increased the total clearance of this drug (from a mean value of 37 ml kg-1 day-1--53 ml kg--1 day--1). 3 The total anticoagulant effect per dose of warfarin, as measured by the area under the effect v time curve, was also reduced by cholestyramine (average reduction of about 25%). 4 Warfarin possibly undergoes enterohepatic recycling in man which can be interrupted by cholestyramine.
Similar articles
-
Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.Clin Pharmacol Ther. 1977 Jun;21(6):731-5. doi: 10.1002/cpt1977216731. Clin Pharmacol Ther. 1977. PMID: 862312
-
Acceleration of the elimination of tenoxicam by cholestyramine in the dog.J Pharmacol Exp Ther. 1986 Jul;238(1):295-301. J Pharmacol Exp Ther. 1986. PMID: 3723402
-
Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration.J Pharm Sci. 1977 Sep;66(9):1275-7. doi: 10.1002/jps.2600660917. J Pharm Sci. 1977. PMID: 903865
-
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.Clin Pharmacokinet. 2005;44(5):467-94. doi: 10.2165/00003088-200544050-00002. Clin Pharmacokinet. 2005. PMID: 15871634 Review.
-
Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.Clin Pharmacokinet. 1986 Nov-Dec;11(6):483-504. doi: 10.2165/00003088-198611060-00005. Clin Pharmacokinet. 1986. PMID: 3542339 Review.
Cited by
-
Clinical pharmacokinetics of oral anticoagulants.Clin Pharmacokinet. 1979 Jan-Feb;4(1):1-15. doi: 10.2165/00003088-197904010-00001. Clin Pharmacokinet. 1979. PMID: 369763 Review.
-
Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.Curr Treat Options Cardiovasc Med. 2005 Jul;7(3):241-50. doi: 10.1007/s11936-005-0052-9. Curr Treat Options Cardiovasc Med. 2005. PMID: 16004855
-
Methods to evaluate biliary excretion of drugs in humans: an updated review.Mol Pharm. 2006 May-Jun;3(3):198-211. doi: 10.1021/mp060011k. Mol Pharm. 2006. PMID: 16749853 Free PMC article. Review.
-
Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.Clin Pharmacokinet. 1989 Apr;16(4):238-53. doi: 10.2165/00003088-198916040-00003. Clin Pharmacokinet. 1989. PMID: 2656051 Review.
-
Clinically important drug interactions with anticoagulants. An update.Clin Pharmacokinet. 1996 Jun;30(6):416-44. doi: 10.2165/00003088-199630060-00002. Clin Pharmacokinet. 1996. PMID: 8792056 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources